Ampyra
(Dalfampridine)ApprovedSmall molecule
Dalfampridine helps improve walking ability in people with multiple sclerosis by strengthening nerve signals that have been damaged by the disease. It works by blocking potassium channels in the nervous system.[2] Ampyra is currently approved and in use across 5 indications[4].[1]
Ampyra is one of 67 small molecule programs targeting Spinal Cord Injury. It is currently in Approved.
5
Indications
14
Total Trials
3
Active Trials
66
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
65 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Ozempic
Novo NordiskApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Elavil
AstraZenecaApproved
Levitra
BayerApproved
Lioresal
NovartisApproved
Calciferol
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ampyra
MMerz North America, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis4 trials
Spinal Cord Injury2 trials
5 more indications
Safety and Efficacy1 trial
Hereditary Spastic Paraplegia1 trial
Adult1 trial
Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults
Completed·—·Phase 2·NCT02656160·13 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 22, 2010
AMPYRA
NDA NDA022250
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ampyra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dalfampridine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- MMerz North America, Inc.